498 related articles for article (PubMed ID: 11207056)
1. Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin.
Flavell DJ; Boehm DA; Noss A; Warnes SL; Flavell SU
Br J Cancer; 2001 Feb; 84(4):571-8. PubMed ID: 11207056
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD7 antibody and immunotoxin treatment of human CD7(+)T-cell leukaemia is significantly less effective in NOD/LtSz-scid mice than in CB.17 scid mice.
Flavell DJ; Warnes SL; Noss AL; Flavell SU
Br J Cancer; 2000 Dec; 83(12):1755-61. PubMed ID: 11104577
[TBL] [Abstract][Full Text] [Related]
3. Host-mediated antibody-dependent cellular cytotoxicity contributes to the in vivo therapeutic efficacy of an anti-CD7-saporin immunotoxin in a severe combined immunodeficient mouse model of human T-cell acute lymphoblastic leukemia.
Flavell DJ; Warnes S; Noss A; Flavell SU
Cancer Res; 1998 Dec; 58(24):5787-94. PubMed ID: 9865737
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
5. Therapy of human B-cell lymphoma bearing SCID mice is more effective with anti-CD19- and anti-CD38-saporin immunotoxins used in combination than with either immunotoxin used alone.
Flavell DJ; Boehm DA; Emery L; Noss A; Ramsay A; Flavell SU
Int J Cancer; 1995 Jul; 62(3):337-44. PubMed ID: 7543082
[TBL] [Abstract][Full Text] [Related]
6. Therapy of human T-cell acute lymphoblastic leukaemia in severe combined immunodeficient mice with two different anti-CD7-saporin immunotoxins containing hindered or non-hindered disulphide cross-linkers.
Flavell DJ; Boehm DA; Okayama K; Kohler JA; Flavell SU
Int J Cancer; 1994 Aug; 58(3):407-14. PubMed ID: 7519586
[TBL] [Abstract][Full Text] [Related]
7. The anti-CD20 antibody rituximab augments the immunospecific therapeutic effectiveness of an anti-CD19 immunotoxin directed against human B-cell lymphoma.
Flavell DJ; Warnes SL; Bryson CJ; Field SA; Noss AL; Packham G; Flavell SU
Br J Haematol; 2006 Jul; 134(2):157-70. PubMed ID: 16771848
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of human acute T-cell leukemia in SCID mice using the anti-CD7-deglycosylated ricin A-chain immunotoxin DA7.
Jansen B; Vallera DA; Jaszcz WB; Nguyen D; Kersey JH
Cancer Res; 1992 Mar; 52(5):1314-21. PubMed ID: 1371092
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness of combinations of bispecific antibodies for delivering saporin to human acute T-cell lymphoblastic leukaemia cell lines via CD7 and CD38 as cellular target molecules.
Flavell DJ; Cooper S; Morland B; French R; Flavell SU
Br J Cancer; 1992 Apr; 65(4):545-51. PubMed ID: 1373293
[TBL] [Abstract][Full Text] [Related]
10. In vivo anti-leukemic efficacy of anti-CD7-pokeweed antiviral protein immunotoxin against human T-lineage acute lymphoblastic leukemia/lymphoma in mice with severe combined immunodeficiency.
Gunther R; Chelstrom LM; Finnegan D; Tuel-Ahlgren L; Irvin JD; Myers DE; Uckun FM
Leukemia; 1993 Feb; 7(2):298-309. PubMed ID: 7678882
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of HB2 (anti-CD7)--saporin immunotoxin in an in vivo model of human T-cell leukaemia developed in severe combined immunodeficient mice.
Morland BJ; Barley J; Boehm D; Flavell SU; Ghaleb N; Kohler JA; Okayama K; Wilkins B; Flavell DJ
Br J Cancer; 1994 Feb; 69(2):279-85. PubMed ID: 7507691
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the potency and therapeutic efficacy of the anti-CD7 immunotoxin HB2-saporin constructed with one or two saporin moieties per immunotoxin molecule.
Flavell DJ; Boehm DA; Noss A; Flavell SU
Br J Cancer; 1997; 75(7):1035-43. PubMed ID: 9083340
[TBL] [Abstract][Full Text] [Related]
13. Preclinical studies with the anti-CD19-saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours.
Flavell DJ; Flavell SU; Boehm DA; Emery L; Noss A; Ling NR; Richardson PR; Hardie D; Wright DH
Br J Cancer; 1995 Dec; 72(6):1373-9. PubMed ID: 8519647
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapy with 3BIT, a triple combination cocktail of anti-CD19, -CD22, and -CD38-saporin immunotoxins, is curative of human B-cell lymphoma in severe combined immunodeficient mice.
Flavell DJ; Noss A; Pulford KA; Ling N; Flavell SU
Cancer Res; 1997 Nov; 57(21):4824-9. PubMed ID: 9354445
[TBL] [Abstract][Full Text] [Related]
15. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
[TBL] [Abstract][Full Text] [Related]
16. CD38 as a target of IB4 mAb carrying saporin-S6: design of an immunotoxin for ex vivo depletion of hematological CD38+ neoplasia.
Bolognesi A; Polito L; Farini V; Bortolotti M; Tazzari PL; Ratta M; Ravaioli A; Horenstein AL; Stirpe F; Battelli MG; Malavasi F
J Biol Regul Homeost Agents; 2005; 19(3-4):145-52. PubMed ID: 16602630
[TBL] [Abstract][Full Text] [Related]
17. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin.
Waurzyniak B; Schneider EA; Tumer N; Yanishevski Y; Gunther R; Chelstrom LM; Wendorf H; Myers DE; Irvin JD; Messinger Y; Ek O; Zeren T; Langlie MC; Evans WE; Uckun FM
Clin Cancer Res; 1997 Jun; 3(6):881-90. PubMed ID: 9815763
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of an anti-CD7-ricin A chain immunoconjugate in a novel murine model of human T-cell leukemia.
Fishwild DM; Aberle S; Bernhard SL; Kung AH
Cancer Res; 1992 Jun; 52(11):3056-62. PubMed ID: 1375534
[TBL] [Abstract][Full Text] [Related]
19. Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.
French RR; Courtenay AE; Ingamells S; Stevenson GT; Glennie MJ
Cancer Res; 1991 May; 51(9):2353-61. PubMed ID: 2015599
[TBL] [Abstract][Full Text] [Related]
20. Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.
Bonardi MA; Bell A; French RR; Gromo G; Hamblin T; Modena D; Tutt AL; Glennie MJ
Int J Cancer Suppl; 1992; 7():73-7. PubMed ID: 1428411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
